Sustained Effects of AXS-05, an Oral NMDA Receptor Antagonist, in Treatment Resistant Depression Patients: Results from the COMET-TRD Trial

Amanda Jones, Cedric O’Gorman, Herriot Tabuteau
Axsome Therapeutics, New York, New York

Introduction

- Major depressive disorder (MDD) is a serious illness.
- MDD is a chronic, disabling, prevalent, and life-threatening illness.
- Currently available oral antidepressants are limited in efficacy.

Trial Objective

- The objective of the COMET-TRD trial was to evaluate the long-term efficacy of open-label AXS-05 treatment in treatment-resistant depression (TRD).

Trial Design

- COMET-TRD was a 6-month, open-label, multicenter trial that evaluated the long-term efficacy and safety of AXS-05 treatment in patients with treatment-resistant depression (TRD).

Efficacy Results

- AXS-05 was associated with a mean MADRS total score reduction of 14.7 points at Week 6, 14.7 points at Week 12, and 20.4 points at Week 24.

Clinical Response over Time (50% Improvement in MADRS)

- Clinical Remission over Time (MADRS total score ≤ 10)

Conclusions

- AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.
- AXS-05 treatment was associated with a mean MADRS total score reduction of 14.7 points at Week 6, 14.7 points at Week 12, and 20.4 points at Week 24.
- The Sheehan Disability Scale (SDS) is a patient-rated scale that assesses functioning in work/school, social life, and family/relationship life.

References

[5] AXS-05 plasma concentration data from the COMET-TRD label trial (N=876) that evaluated the long-term efficacy and safety of AXS-05 treatment in patients with treatment-resistant depression (TRD).

AXS-05: A Novel, Oral NMDA Receptor Antagonist with Multimodal Activity

- AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.
- AXS-05 treatment was associated with a mean MADRS total score reduction of 14.7 points at Week 6, 14.7 points at Week 12, and 20.4 points atWeek 24.

Baseline Demographics and Clinical Characteristics

- AXS-05 (N=351) vs. AXS-05 (N=70)

Clinical Remission over Time (MADRS total score ≤ 10)

- The Sheehan Disability Scale (SDS) is a patient-rated scale that assesses functioning in work/school, social life, and family/relationship life.

AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. AXS-05 treatment was associated with a mean MADRS total score reduction of 14.7 points at Week 6, 14.7 points at Week 12, and 20.4 points at Week 24.

References

[5] AXS-05 plasma concentration data from the COMET-TRD label trial (N=876) that evaluated the long-term efficacy and safety of AXS-05 treatment in patients with treatment-resistant depression (TRD).

AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.

- AXS-05 treatment was associated with a mean MADRS total score reduction of 14.7 points at Week 6, 14.7 points at Week 12, and 20.4 points at Week 24.

Baseline Demographics and Clinical Characteristics

- AXS-05 (N=351) vs. AXS-05 (N=70)

Clinical Remission over Time (MADRS total score ≤ 10)

- The Sheehan Disability Scale (SDS) is a patient-rated scale that assesses functioning in work/school, social life, and family/relationship life.

AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. AXS-05 treatment was associated with a mean MADRS total score reduction of 14.7 points at Week 6, 14.7 points at Week 12, and 20.4 points at Week 24.

References

[5] AXS-05 plasma concentration data from the COMET-TRD label trial (N=876) that evaluated the long-term efficacy and safety of AXS-05 treatment in patients with treatment-resistant depression (TRD).